strategies research. The research conducted under this clearance falls primarily under the Bureau of Economics within the FTC, but other divisions or bureaus within the FTC may offer advice and input into the research conducted. The research would not be conducted specifically for the purposes of making policy or regulatory decisions or for allocating or redirecting significant resources to support these decisions. Rather, the FTC's Bureau of Economics will use such studies to test communications and social and behavioral methods about consumer behavior and beliefs in ways that increase our understanding of the economic effects of regulation as well as ways in which business practices may be currently, or have the potential to be, inflicting harm on consumers. As one example, the FTC intends to use this PRA to survey American consumers about their experiences of fraud in the marketplace.

Burden statement: Annually, the FTC projects about 10 social and behavioral studies using the variety of test methods listed in this document. The variety of test methods is needed to give the FTC sufficient flexibility so that the FTC can effectively gather information from the public and enhance the effectiveness of the FTC's regulatory and communications programs.

The FTC estimates the burden of this collection of information as follows:

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN

Activity	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response (minutes)	Total hours
Interviews/Surveys	20,000	1	20,000	30	10,000

Staff believes that there are no current start-up costs or other capital costs associated with this collection of information.

Request for Comment

On July 8, 2025, the FTC sought public comment on the proposed information collections associated with this generic clearance request. 90 FR 30072. Four comments were received in response to the notice in the **Federal Register**. All four comments supported the proposed generic information collection plan, while offering suggestions on how the information collection can be most effective. One anonymous comment emphasized clear language instructions to survey participants,[1] which is a standard that the FTC will follow when designing survey and experiment instruments under this proposed information collection.

A comment from the Cantor Institute emphasized the need for statistical performance goals and commitments that ''safeguard data quality, replicability, and privacy at scale.'' [2] The Supporting Statement Part B that will be separately submitted to OMB on the same date as the publication of this **Federal Register** notice aims to address these concerns, while the Generic Information Collection Template, which will accompany any future information collection, also commits any related Information Collection to a high statistical standard.[3] The Cantor Institute also argued that the initial **Federal Register** notice likely understated the burden to respondents. The FTC politely disagrees with this argument, as the stated averages per respondent are calculated to be an average across all respondents, including the burden associated with screening questions and partially completed responses.

A comment from Mary Sullivan at George Washington University supported the proposed generic information collection because ''when a new practice is emerging that might require FTC action, it is critical to obtain information about the practice quickly to minimize possible harm to consumers.'' [4] The FTC agrees with this statement.

Finally, an anonymous comment recommended increasing the number of responses from 20,000 to 250,000.[5] In the interest of reducing the burden on the public and the strain on government resources, the FTC declines to adopt this suggestion.

Pursuant to OMB regulations, 5 CFR part 1320, that implement the PRA, 44 U.S.C. 3501 *et seq.,* the FTC is providing this second opportunity for public comment while seeking OMB approval to engage in the proposed information collections.

Your comment—including your name and your state—will be placed on the public record of this proceeding. Because your comment will be made public, you are solely responsible for making sure that your comment does not include any sensitive personal information, such as anyone's Social Security number; date of birth; driver's license number or other state identification number, or foreign country equivalent; passport number; financial account number; or credit or debit card number. You are also solely responsible for making sure that your comment does not include any sensitive health information, such as medical records or other individually identifiable health information. In addition, your comment should not include any ''trade secret or any commercial or financial information which . . . is privileged or confidential''—as provided by Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)—including in particular competitively sensitive information such as costs, sales statistics, inventories, formulas, patterns, devices, manufacturing processes, or customer names.

Josephine Liu,

Assistant General Counsel for Legal Counsel.

[FR Doc. 2026–12502 Filed 6–18–26; 8:45 am]

BILLING CODE 6750–01–P

[1] Comment ID FTC–2025–0132–0002 (Anonymous), received July 30, 2025.

[2] Comment ID FTC–2025–0132–0004 (Cantor Institute), received Aug. 19, 2025.

[3] If OMB approves the overall generic clearance for this proposed collection, the FTC will thereafter submit a short Generic Information Collection Template for each specific information collection request to be conducted under that generic clearance and obtain OMB's approval for the proposed specific collection.

[4] Comment ID FTC–2025–0132–0005 (Mary Sullivan), received Aug. 25, 2025.

[5] Comment ID FTC–2025–0132–0006 (Anonymous), received Sept. 8, 2025.

FEDERAL TRADE COMMISSION

Agency Information Collection Activities; Proposed Collection; Comment Request; Extension

AGENCY: Federal Trade Commission.

ACTION: Notice and request for comment.

SUMMARY: The Federal Trade Commission (FTC or Commission) is seeking public comment on its proposal

requesting that the Office of Management and Budget (OMB) extend for three years the current Paperwork Reduction Act (PRA) clearance for information collection requirements of its Rule Governing Pre-Sale Availability of Written Warranty Terms. The current clearance expires on July 31, 2026.

DATES: Comments must be received by July 22, 2026.

ADDRESSES: Interested parties may file a comment online or on paper, by following the instructions in the **SUPPLEMENTARY INFORMATION** section below. Written comments and recommendations for the proposed information collection should be sent within 30 days of publication of this notice to *www.reginfo.gov/public/do/PRAMain.* Find this particular information collection and its accompanying supporting statement by selecting ''Currently under 30-day Review—Open for Public Comments'' or by using the search function. The reginfo.gov web link is a United States Government website produced by OMB and the General Services Administration (GSA). Under PRA requirements, OMB's Office of Information and Regulatory Affairs (OIRA) reviews Federal information collections.

FOR FURTHER INFORMATION CONTACT: Sung W. Kim, Attorney, Division of Marketing Practices, Bureau of Consumer Protection, Federal Trade Commission, 600 Pennsylvania Avenue NW, Washington, DC 20580, (202) 326–2211; *skim6@ftc.gov.*

SUPPLEMENTARY INFORMATION:

Title: Pre-Sale Availability of Written Warranty Terms (Pre-Sale Availability Rule or Rule), 16 CFR part 702.

OMB Control Number: 3084–0112.

Type of Review: Extension of currently approved collection.

Affected Public: Businesses and other for-profit entities.

Estimated Annual Burden Hours: 2,611,826 hours (143,721 hours for manufacturers + 2,468,105 hours for retailers).

- Manufacturers account for approximately 143,721 hours (26,131 manufacturers × 5.5 hours)
- Retailers account for approximately 2,468,105 hours (493,621 retailers × 5.0 burden hours)

Estimated Annual Labor Costs: $74,437,041 (which is derived from $39,177,390 for sales associates + $35,259,651 for clerical workers) [1]

- *Sales Associates:* 1,305,913 hours × $30/hour = $39,177,390
- *Clerical Workers:* 1,305,913 hours × $27/hour = $35,259,651

Estimated Annual Non-Labor Costs: De minimis.

Abstract

The Pre-Sale Availability Rule, 16 CFR part 702 (Pre-Sale Availability Rule or Rule) requires sellers and warrantors to make the text of any written warranty on a consumer product costing more than $15 available to the consumer before sale. The Rule has no recordkeeping or reporting requirements. On March 30, 2026, the Commission sought comment on the disclosure requirements associated with the Rule. 91 FR 15616. No relevant comments were received.

Pursuant to the OMB regulations, 5 CFR part 1320, that implement the PRA, 44 U.S.C. 3501 *et seq.,* the FTC is providing this second opportunity for public comment while seeking OMB approval to renew the pre-existing clearance for the information collection requirements associated with this Rule.

Your comment—including your name and your state—will be placed on the public record of this proceeding. Because your comment will be made public, you are solely responsible for making sure that your comment does not include any sensitive personal information, such as anyone's Social Security number; date of birth; driver's license number or other state identification number, or foreign country equivalent; passport number; financial account number; or credit or debit card number. You are also solely responsible for making sure that your comment does not include any sensitive health information, such as medical records or other individually identifiable health information. In addition, your comment should not include any ''trade secret or any commercial or financial information which . . . is privileged or confidential''—as provided by Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)—including in particular competitively sensitive information such as costs, sales statistics, inventories, formulas, patterns, devices, manufacturing processes, or customer names.

Josephine Liu,

Assistant General Counsel for Legal Counsel.

[FR Doc. 2026–12503 Filed 6–18–26; 8:45 am]

BILLING CODE 6750–01–P

[1] This estimate is updated from the prior estimate of $73,131,128 that was included in the 60-day **Federal Register** notice and is based on more current information from the Bureau of Labor Statistics. *See* Table 1. National employment and wage data from the Occupational Employment Statistics survey by occupation, May 2025, at *https://www.bls.gov/news.release/ocwage.t01.htm,* which was made publicly available on May 15, 2026.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–6402]

Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA or Agency) is withdrawing approval of new drug application (NDA) for TAZVERIK (tazemetostat) tablet, 200 milligrams (mg), held by Epizyme, Inc., an Ipsen Company (Epizyme), 1 Main St., Cambridge, MA 02142. Epizyme has voluntarily requested withdrawal of its NDA and has waived the expedited withdrawal procedures.

DATES: Approval is withdrawn as of June 22, 2026.

FOR FURTHER INFORMATION CONTACT: Kimberly Lehrfeld, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6250, Silver Spring, MD 20993–0002, 301–796–3137, *Kimberly.Lehrfeld@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION: On January 23, 2020, FDA approved NDA 211723 for TAZVERIK (tazemetostat) tablet, 200 mg, for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection, under the Agency's accelerated approval pathway pursuant to section 506(c) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 356(c)) and 21 CFR 314.510. On June 18, 2020, FDA approved the following two new indications for TAZVERIK (tazemetostat) tablet, 200 mg,[1] also

[1] The indications approved for TAZVERIK (tazemetostat) tablet on June 18, 2020, were approved under a Type 9 NDA, 213400 (Manual of Policies and Procedures 5018.2 NDA Classification Codes). This NDA was administratively closed at approval and the indications and all regulatory requirements were inherited by the parent NDA, 211723. TAZVERIK (tazemetostat) tablets were only marketed with these indications under NDA 211723.